152 related articles for article (PubMed ID: 22623146)
1. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
3. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
4. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.
Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF
Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185
[TBL] [Abstract][Full Text] [Related]
5. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
[TBL] [Abstract][Full Text] [Related]
6. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
[TBL] [Abstract][Full Text] [Related]
7. PET imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133).
Toomey JS; Bhatia S; Moon LT; Orchard EA; Tainter KH; Lokitz SJ; Terry T; Mathis JM; Penman AD
PLoS One; 2012; 7(6):e39041. PubMed ID: 22723923
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.
Hsiao IT; Weng YH; Lin WY; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lu CS; Lin KJ
Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330
[TBL] [Abstract][Full Text] [Related]
9. Deuterated
Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
[TBL] [Abstract][Full Text] [Related]
10. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons.
Xu Y; Tang J; Liu C; Zhao C; Cao S; Yu H; Chen Z; Xie M
Nucl Med Biol; 2021; 96-97():9-18. PubMed ID: 33647803
[TBL] [Abstract][Full Text] [Related]
11. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats.
Tsao HH; Lin KJ; Juang JH; Skovronsky DM; Yen TC; Wey SP; Kung MP
Nucl Med Biol; 2010 May; 37(4):413-9. PubMed ID: 20447551
[TBL] [Abstract][Full Text] [Related]
12. PET imaging with [
Tang J; Xu Y; Liu C; Fang Y; Cao S; Zhao C; Huang H; Zou M; Chen Z
Nucl Med Biol; 2020; 90-91():1-9. PubMed ID: 32861175
[TBL] [Abstract][Full Text] [Related]
13. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
[TBL] [Abstract][Full Text] [Related]
14. [
Weng CC; Huang SL; Chen ZA; Lin KJ; Hsiao IT; Yen TC; Kung MP; Wey SP; Hsu CH
Ann Nucl Med; 2017 Aug; 31(7):506-513. PubMed ID: 28451991
[TBL] [Abstract][Full Text] [Related]
15. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
[TBL] [Abstract][Full Text] [Related]
16. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.
Wang JL; Oya S; Parhi AK; Lieberman BP; Ploessl K; Hou C; Kung HF
Nucl Med Biol; 2010 May; 37(4):479-86. PubMed ID: 20447560
[TBL] [Abstract][Full Text] [Related]
17. Parkinson׳s disease-related modulation of functional connectivity associated with the striatum in the resting state in a nonhuman primate model.
Li J; Luo C; Chen Y; Chen Q; Huang R; Sun J; Gong Q; Wu X; Qi Z; Liang Z; Li L; Li H; Li P; Wang W; Shang HF
Brain Res; 2014 Mar; 1555():10-9. PubMed ID: 24530271
[TBL] [Abstract][Full Text] [Related]
18. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
[TBL] [Abstract][Full Text] [Related]
19. Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [(18)F]AV-133 in mouse brain.
Wu X; Zhou X; Zhang S; Zhang Y; Deng A; Han J; Zhu L; Kung HF; Qiao J
Nucl Med Biol; 2015 Jul; 42(7):630-6. PubMed ID: 25910857
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.
Masilamoni G; Votaw J; Howell L; Villalba RM; Goodman M; Voll RJ; Stehouwer J; Wichmann T; Smith Y
Exp Neurol; 2010 Dec; 226(2):265-73. PubMed ID: 20832405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
